Skip to main content

Advertisement

Table 1 Baseline cohort characteristics

From: Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis

Variable Number Value
Age, median (IQRa), years 331 60 (49.4–68.6)
Age ≥65 years, n (%) 331 122 (36.9)
Women, n (%) 331 205 (61.9)
Current smoker, n (%) 330 69 (20.9)
Symptom duration, median (IQR), months 331 3.1 (1.7–5.7)
Body mass index, median (IQR), kg/m2 309 26.1 (23–29.8)
 25–29.9, n (%)   104 (33.7)
 ≥30, n (%)   74 (23.9)
Swollen joint count, 28 joints, median (IQR) 330 9 (5–15)
Tender joint count, 28 joints, median (IQR) 329 9 (4–16)
Fulfilling 1987 ACR criteria for rheumatoid arthritis, n (%) 331 275 (83.1)
Fulfilling 2010 EULAR/ACR criteria for rheumatoid arthritis, n (%) 330 281 (85.2)
Fulfilling 1987 or 2010 sets of criteria for rheumatoid arthritis, n (%) 330 304 (92.1)
Disease Activity Score, 28 joints-C-reactive protein, median (IQR) 328 5.1 (4.2–6.2)
Simplified Disease Activity Index, median (IQR) 328 30.1 (19.8–45.2)
Modified Health Assessment Questionnaire, median (IQR) 329 0.8 (0.4–1.4)
Total SvH score, median (IQR) 328 2 (0–6)
SvH erosion score, median (IQR) 328 1 (0–3)
Erythrocyte sedimentation rate, mm/h, median (IQR) 331 33 (17–46)
C-reactive protein, mg/L, median (IQR) 331 13.1 (4.5–32.0)
C-reactive protein >8.0 mg/L 331 207 (62.5)
Rheumatoid factor-positive, ≥40 IU/ml 331 146 (44.1)
Anti-CCP2 positive 331 133 (40.2)
Anti-Sa positive 331 73 (22.1)
14-3-3η, ng/ml, median (IQR) 331 0.1 (0.0–1.9)
14-3-3η positive, ≥0.19 ng/ml 331 153 (46.2)
14-3-3η positive, ≥0.50 ng/ml 331 119 (36.0)
  1. a IQR 25th–75th percentiles. ACR American College of Rheumatology. EULAR European League Against Rheumatism, Anti-CCP2 antibodies to citrullinated peptides, second generation. SvH Sharp score modified by van der Heijde